Regency Capital Management Inc. DE increased its stake in VectivBio Holding AG (NASDAQ:VECT - Free Report) by 1,600.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 510,000 shares of the company's stock after purchasing an additional 480,000 shares during the period. VectivBio makes up 5.5% of Regency Capital Management Inc. DE's holdings, making the stock its 3rd biggest holding. Regency Capital Management Inc. DE's holdings in VectivBio were worth $8,594,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also bought and sold shares of the company. Alliancebernstein L.P. acquired a new stake in VectivBio during the 2nd quarter worth approximately $21,659,000. Goldman Sachs Group Inc. grew its position in shares of VectivBio by 4,049.8% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,123,647 shares of the company's stock worth $18,956,000 after buying an additional 1,096,570 shares during the period. Marshall Wace LLP raised its stake in VectivBio by 172.5% during the 4th quarter. Marshall Wace LLP now owns 1,369,656 shares of the company's stock worth $11,793,000 after buying an additional 867,000 shares during the period. Ergoteles LLC acquired a new stake in VectivBio in the 2nd quarter valued at $7,489,000. Finally, Citadel Advisors LLC increased its holdings in VectivBio by 15.4% during the 2nd quarter. Citadel Advisors LLC now owns 3,143,237 shares of the company's stock worth $16,973,000 after purchasing an additional 420,591 shares in the last quarter.
VectivBio Price Performance
VECT stock remained flat at $16.85 during trading on Wednesday. The business has a fifty day moving average of $16.85 and a 200-day moving average of $16.85. VectivBio Holding AG has a 12-month low of $4.25 and a 12-month high of $16.98.
VectivBio Profile
(
Free Report)
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider VectivBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VectivBio wasn't on the list.
While VectivBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
